BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K; GE Adenocarcinoma Meta-analysis Group. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:CD008107. [PMID: 23728671 DOI: 10.1002/14651858.cd008107.pub2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Kang SY, Hwang D, Shin S, Park J, Kim M, Rahman MDH, Rahman MA, Ko SG, Kim B. Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets. Cancers (Basel) 2021;13:4502. [PMID: 34572730 DOI: 10.3390/cancers13184502] [Reference Citation Analysis]
2 Raakow J, Denecke C, Chopra S, Fritz J, Hofmann T, Andreou A, Thuss-Patience P, Pratschke J, Biebl M. [Laparoscopic versus open gastrectomy for advanced gastric cancer : Operative and postoperative results]. Chirurg 2020;91:252-61. [PMID: 31654103 DOI: 10.1007/s00104-019-01053-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Soleyman-Jahi S, Abdirad A, Fallah AA, Ghasemi S, Sadeghi F, Heidari R, Mahmoodzadeh H, Zendehdel K. Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study. Clin Transl Gastroenterol 2017;8:e209. [PMID: 28055030 DOI: 10.1038/ctg.2016.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
4 Simoni N, Pavarana M, Micera R, Weindelmayer J, Mengardo V, Rossi G, Cenzi D, Tomezzoli A, Del Bianco P, Giacopuzzi S, De Manzoni G, Mazzarotto R. Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. Cancers (Basel) 2020;12:E3614. [PMID: 33287147 DOI: 10.3390/cancers12123614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
6 Gamboa AC, Winer JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.Cancers (Basel). 2019;11:1662. [PMID: 31717799 DOI: 10.3390/cancers11111662] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Smith WH, Pintova S, DiMaio CJ, Manolas P, Lee DS, Hiotis SP, Kartsonis M, Holcombe RF, Dharmarajan KV. An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med 2015;2015:941508. [PMID: 26770853 DOI: 10.1155/2015/941508] [Reference Citation Analysis]
8 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
9 van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel) 2019;11:E80. [PMID: 30641964 DOI: 10.3390/cancers11010080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
10 Sakin A, Atci MM, Aldemir MN, Akagündüz B, Şahin S, Arıcı S, Secmeler S, Cihan S. The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy. Cureus 2021;13:e14639. [PMID: 34046274 DOI: 10.7759/cureus.14639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sah BK, Xu W, Zhang B, Zhang H, Yuan F, Li J, Liu W, Yan C, Li C, Yan M, Zhu Z. Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China. Front Oncol 2020;10:567529. [PMID: 33537232 DOI: 10.3389/fonc.2020.567529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 van Straten D, Mashayekhi V, de Bruijn HS, Oliveira S, Robinson DJ. Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) 2017;9:E19. [PMID: 28218708 DOI: 10.3390/cancers9020019] [Cited by in Crossref: 355] [Cited by in F6Publishing: 295] [Article Influence: 71.0] [Reference Citation Analysis]
13 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
14 Glatz T, Marjanovic G, Zirlik K, Brunner T, Hopt UT, Makowiec F, Hoeppner J. [Surgical treatment of esophageal cancer : Evolution of management and prognosis over the last 3 decades]. Chirurg 2015;86:662-9. [PMID: 25312491 DOI: 10.1007/s00104-014-2877-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer 2017;17:21-32. [PMID: 28337360 DOI: 10.5230/jgc.2017.17.e3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Koch C, Reitz C, Schreckenbach T, Eichler K, Filmann N, Al-Batran SE, Götze T, Zeuzem S, Bechstein WO, Kraus T, Bojunga J, Düx M, Trojan J, Blumenstein I. Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma. PLoS One 2019;14:e0223613. [PMID: 31639132 DOI: 10.1371/journal.pone.0223613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Coccolini F, Fugazzola P, Ansaloni L, Sartelli M, Cicuttin E, Leandro G, De' Angelis GL, Gaiani F, Di Mario F, Tomasoni M, Catena F. Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy. Acta Biomed 2018;89:104-9. [PMID: 30561427 DOI: 10.23750/abm.v89i8-S.7904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Matuszcak C, Haier J, Hummel R, Lindner K. MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014; 20(38): 13658-13666 [PMID: 25320504 DOI: 10.3748/wjg.v20.i38.13658] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
20 Mongan AM, Lynam-Lennon N, Casey R, Maher S, Pidgeon G, Reynolds JV, O'Sullivan J. Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma. Clin Transl Oncol 2016;18:632-40. [PMID: 26474871 DOI: 10.1007/s12094-015-1411-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Guner A. Recent trends of gastric cancer treatment in Turkey. Transl Gastroenterol Hepatol 2017;2:31. [PMID: 28529985 DOI: 10.21037/tgh.2017.04.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
22 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Mann C, Hadzijusufovic E, Lang H, Grimminger PP. Fully robotic Ivor-Lewis esophagectomy (RAMIE4) for esophageal cancer after emergency surgery and ligation of the gastroduodenal artery. J Int Med Res 2019;47:1025-9. [PMID: 30543139 DOI: 10.1177/0300060518814682] [Reference Citation Analysis]
24 Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, Rahman S, Devonshire G, Lloyd MA, Walters ZS, Fitzgerald RC, Rose-Zerilli MJJ, Underwood TJ, On Behalf Of Occams. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:3394. [PMID: 34298611 DOI: 10.3390/cancers13143394] [Reference Citation Analysis]
25 Boldrin E, Curtarello M, Dallan M, Alfieri R, Realdon S, Fassan M, Saggioro D. Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients. Int J Mol Sci 2020;21:E1547. [PMID: 32102481 DOI: 10.3390/ijms21041547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
27 Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, Pugliese R, Ferrari G. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8:1018-1025. [PMID: 29299362 DOI: 10.21037/jgo.2017.08.13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
28 Haverkamp L, Brenkman HJ, Seesing MF, Gisbertz SS, van Berge Henegouwen MI, Luyer MD, Nieuwenhuijzen GA, Wijnhoven BP, van Lanschot JJ, de Steur WO. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer. 2015;15:556. [PMID: 26219670 DOI: 10.1186/s12885-015-1551-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
29 Biebl M, Andreou A, Chopra S, Denecke C, Pratschke J. Upper Gastrointestinal Surgery: Robotic Surgery versus Laparoscopic Procedures for Esophageal Malignancy. Visc Med 2018;34:10-5. [PMID: 29594164 DOI: 10.1159/000487011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
30 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
31 Wu Y, Li J. Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery. Cancer Manag Res 2021;13:2433-45. [PMID: 33758542 DOI: 10.2147/CMAR.S295646] [Reference Citation Analysis]
32 Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, Shi M, Xu W, Zhu Z, Liu W, Yan C, Li C, Liu B, Yan M. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11:6093. [PMID: 33257672 DOI: 10.1038/s41467-020-19965-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Bollschweiler E, Hölscher AH, Schmidt M, Warnecke-Eberz U. Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res 2015;27:221-30. [PMID: 26157318 DOI: 10.3978/j.issn.1000-9604.2015.04.04] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
34 Nusrath S, Thammineedi SR, Vijaya Narsimha Raju KV, Patnaik SC, Pawar S, Santa A, Rajappa SJ, Mallavarapu KM, Raju K, Murthy S. Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. Rambam Maimonides Med J 2019;10. [PMID: 29993360 DOI: 10.5041/RMMJ.10339] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ 2017;356:j573. [PMID: 28258124 DOI: 10.1136/bmj.j573] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 13.6] [Reference Citation Analysis]
36 Beeharry MK, Ni ZT, Yang ZY, Zheng YN, Feng RH, Liu WT, Yan C, Yao XX, Li C, Yan M, Zhu ZG. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial. BMC Cancer 2020;20:224. [PMID: 32183736 DOI: 10.1186/s12885-020-6701-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 2015;12:115-24. [PMID: 25384943 DOI: 10.1038/nrclinonc.2014.191] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 10.5] [Reference Citation Analysis]
38 Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016;16:503. [PMID: 27435280 DOI: 10.1186/s12885-016-2564-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
39 Wang X, Li X, Zhou N, Zhong D, Bai C, Zhao L. Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Ann Transl Med 2019;7:546. [PMID: 31807528 DOI: 10.21037/atm.2019.09.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
41 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol 2016; 22(3): 1139-1159 [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
42 Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res Pract 2015;2015:404203. [PMID: 26448741 DOI: 10.1155/2015/404203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Brown AM, Giugliano DN, Berger AC, Pucci MJ, Palazzo F. Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. Langenbecks Arch Surg. 2017;402:1153-1158. [PMID: 28803334 DOI: 10.1007/s00423-017-1610-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
44 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
45 Hölscher AH, Babic B. New approaches in esophageal carcinomas. Innov Surg Sci 2016;1:87-95. [PMID: 31579724 DOI: 10.1515/iss-2016-0020] [Reference Citation Analysis]
46 Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol 2020;18:51. [PMID: 32151257 DOI: 10.1186/s12957-020-01819-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
47 Choi JH, Suh YS, Choi Y, Han J, Kim TH, Park SH, Kong SH, Lee HJ, Yang HK. Comprehensive Analysis of the Neutrophil-to-Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer. World J Surg. 2018;42:2530-2541. [PMID: 29392430 DOI: 10.1007/s00268-018-4510-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
48 Choi M, Ishizawa S, Kraemer D, Sasson A, Feinberg E. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis. Eur J Surg Oncol 2021:S0748-7983(21)00682-X. [PMID: 34446344 DOI: 10.1016/j.ejso.2021.08.012] [Reference Citation Analysis]
49 Gabriel E, Attwood K, Du W, Tuttle R, Alnaji RM, Nurkin S, Malhotra U, Hochwald SN, Kukar M. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. JAMA Surg 2016;151:234-45. [PMID: 26559488 DOI: 10.1001/jamasurg.2015.4068] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
50 Di Leo A, Zanoni A. Siewert III adenocarcinoma: treatment update. Updates Surg. 2017;69:319-325. [PMID: 28303519 DOI: 10.1007/s13304-017-0429-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
51 Glatz T, Verst R, Kuvendjiska J, Bronsert P, Becker H, Hoeppner J, Kulemann B. Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials. J Clin Med 2020;9:E2654. [PMID: 32824326 DOI: 10.3390/jcm9082654] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
53 Manzini G, Henne-Bruns D, Kremer M. Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials. BMJ Open Gastroenterol. 2017;4:e000138. [PMID: 29177062 DOI: 10.1136/bmjgast-2017-000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014;55:7-8, 10-4. [PMID: 24154497 DOI: 10.1007/s00108-013-3315-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Yeo ST, Bray N, Haboubi H, Hoare Z, Edwards RT. Endoscopic ultrasound staging in patients with gastro-oesophageal cancers: a systematic review of economic evidence. BMC Cancer 2019;19:900. [PMID: 31500592 DOI: 10.1186/s12885-019-6116-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 2018;194:125-35. [PMID: 29071366 DOI: 10.1007/s00066-017-1225-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]